Reformulation of current recommendations for target serum lithium concentration according to clinical indication, age and physical comorbidity

Australian and New Zealand Journal of Psychiatry

Volumn 45, Issue 12, 2011, Pages 1026-1032

  Wijeratne, Chanaka ^a   Draper, Brian ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Bipolar; Lithium; Serum monitoring

Indexed keywords

ARIPIPRAZOLE; CREATININE; CYCLOOXYGENASE 2 INHIBITOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HALOPERIDOL; LITHIUM; MOOD STABILIZER; NONSTEROID ANTIINFLAMMATORY AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; THIAZIDE DIURETIC AGENT; VALPROIC ACID;

AGE; BIPOLAR DISORDER; COMORBIDITY; DIABETES INSIPIDUS; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MONITORING; DRUG TOLERABILITY; KIDNEY FUNCTION; MAJOR DEPRESSION; MANIA; MOOD DISORDER; PRACTICE GUIDELINE; REVIEW; THYROID DISEASE; THYROID FUNCTION; TREATMENT INDICATION;

AGE FACTORS; COMORBIDITY; DRUG THERAPY, COMBINATION; DRUG TOXICITY; HUMANS; LITHIUM COMPOUNDS; MOOD DISORDERS; PRACTICE GUIDELINES AS TOPIC; RISK FACTORS;

EID: 82355160662     PISSN: 00048674     EISSN: 14401614     Source Type: Journal    
DOI: 10.3109/00048674.2011.610296     Document Type: Review

References (48)

1. Cade J. Lithium salts in the treatment of psychotic excitement. Med J Aust 1949; 2:349-352.
2. Bauer M, Mitchner L. What is a 'mood stabilizer'? An evidencebased response. Am J Psychiatry 2004; 161:3-18. (Pubitemid 38419301)
3. Price L, Carpenter L, Tyrka A. Lithium augmentation for refractory depression: a critical reappraisal. Primary Psychiatry 2008; 15:35-42.
4. Cipriani A, Pretty H, Hawton K, Geddes J. Lithium in the prevention of suicidal behaviour and all-cause mortality in patients with mood disorders: a systematic review of randomized trials. Am J Psychiatry 2005; 162:1805-1819. (Pubitemid 41428610)
5. Malhi G, Adams D, Berk M. Is lithium in a class of its own? A brief profi le of its clinical use. A ust N Z J Psychiatry 2009; 43:1096-1104.
6. Tohen M, Chengappa K, Suppes T et al. Effi cacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy. Arch Gen Psychiatry 2002; 59:62-69. (Pubitemid 34044408)
7. Shulman K, Rochon P, Sykora K et al. Changing prescription patterns for lithium and valproic acid in old age: shifting practice without evidence. BMJ 2003; 326:960-961. (Pubitemid 36543193)
8. Mitchell P. Therapeutic drug monitoring of psychotropic medications. Br J Clin Pharm 2001; 52:S45-S54.
9. Adityanjee, Munshi K, Thampy A. The syndrome of irreversible lithium-effectuated neurotoxicity. Clin Neuropharm 2005; 28:38-49. (Pubitemid 40276820)
10. Lindeman R, Tobin J, Shock N. Longitudinal studies on the rate of decline in renal function with age. J Am Ger Soc 1985; 33:278-285. (Pubitemid 15087125)
11. Chen L, Pym H. Rapid onset of neurological symptoms and lithium toxicity on starting meloxicam. A ust N Z J Psychiatry 2010; 44: 95-95.
12. Sachs G, Gardner-Schuster E. Adjunctive treatment of acute mania: a clinical overview. Acta Psychiatr Scand 2007; 116:27-34. (Pubitemid 47231066)
13. Amdisen A. Serum level monitoring and clinical pharmacokinetics of lithium. Clin Pharmacokinetics 1977; 2:73-92. (Pubitemid 8097928)
14. Malhi GS, Tanious M. Optimal frequency of lithium administration in the treatment of bipolar disorder. Clinical and dosing considerations. CNS Drugs 2011; 25:289-298.
15. Schou M. Lithium in psychiatric therapy. Stock-taking after ten years. Psychopharmacologia 1959; 1:65-78.
16. Schou M. Foreword. A ust N Z J Psychiatry 1999; 33:S1-S3. (Pubitemid 30015870)
17. Birch N, Grof P, Hullin R, Kehoe R, Schou M, Srinivasan D. Lithium prophylaxis: proposed guidelines for good clinical practice. Lithium 1993; 4:225-230. (Pubitemid 23348752)
18. American Psychiatric Association. T reatment of patients with bipolar disorder, second edition. Washington, DC: American Psychiatric Press, 2002.
19. NICE. Bipolar disorder: the management of bipolar disorder in adults, children and adolescents, in primary and secondary care. London: National Institute for Health and Clinical Excellence, 2006.
20. Royal Australian and New Zealand College of Psychiatrists Clinical Practice Guidelines Team for Bipolar Disorder. Australian and New Zealand clinical practice guidelines for the treatment of bipolar disorder. A ust N Z J Psychiatry 2004; 38:280-305.
21. Yatham L, Kennedy S, Schaffer A et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009. Bipolar Dis 2009; 11:225-255.
22. Ng F, Mammen O, Wilting I et al. The International Society for Bipolar Disorders (ISBD) consensus guidelines for the safety monitoring of bipolar disorder treatments. Bipolar Dis 2009; 11:559-595.
23. Bowden C, Brugger A, Swann A et al. Effi cacy of divalproex versus lithium and placebo in the treatment of mania. JAMA 1994; 271:918-924. (Pubitemid 24083217)
24. Bowden C, Grunze H, Mullen J et al. A randomized, double-blind, placebo-controlled effi cacy and safety study of quetiapine or lithium as monotherapy for mania in bipolar disorder. J Clin Psychiatry 2005; 66:111-121.
25. Ketter T, Wang P, Nowakowska C, Marsh W, Bonner J. Treatment of acute mania in bipolar disorder. In: Ketter T, ed. Advances in Treatment of Bipolar Disorder. Washington, DC: American Psychiatric Publishing, 2005.
26. Sachs G, Grossman F, Ghaemi S, Okamoto A, Bowden C. Combination of a mood stabilizer with risperidone or haloperidol for treatment of acute mania: a double-blind, placebo-controlled comparison of effi cacy and safety. Am J Psychiatry 2002; 159: 1146-1154. (Pubitemid 34743254)
27. Yatham L, Grossman F, Augustyns I, Vieta E, Ravindran A. Mood stabilisers plus risperidone or placebo in the treatment of acute mania. Br J Psychiatry 2003; 182:141-147.
28. Sachs G, Chengappa K, Suppes T et al. Quetiapine with lithium or divalproex for the treatment of bipolar mania: a randomized, doubleblind, placebo-controlled study. Bipolar Dis 2004; 6:213-223. (Pubitemid 38702297)
29. Yatham L, Paulsson B, Mullen J, Vagero M. Quetiapine versus placebo in combination with lithium or divalproex for the treatment of bipolar mania. J Clin Psychopharm 2004; 24:599-606. (Pubitemid 39518654)
30. Vieta E, T'joen C, McQuade R et al. Effi cacy of adjunctive aripiprazole to either valproate or lithium in bipolar mania patients partially nonresponsive to valproate/lithium monotherapy: a placebo- controlled study. Am J Psychiatry 2008; 165:1316-1325.
31. Severus W, Kleindeinst N, Seemuller F, Frangou S, Moller H, Greil W. What is the optimal serum lithium level in the long-term treatment of bipolar disorder-A review? Bipolar Dis 2008; 10:231-237. (Pubitemid 351637686)
32. Geddes J, Goodwin G, Rendell J et al. Lithium plus valproate combination therapy versus monotherapy for relapse prevention in bipolar I disorder (BALANCE): a randomised open-label trial. Lancet 2010; 375:385-395.
33. Nierenberg A, Sylvia L, Leon A et al. Lithium treatment-moderate dose use study (LiTMUS) for bipolar disorder: rationale and design. Clinical Trials 2009; 6:637-648.
34. Gelenberg A, Kane J, Keller M et al. Comparison of standard and low serum levels of lithium for maintenance treatment of bipolar depression. New Engl J Med 1989; 321:1489-1493. (Pubitemid 20015538)
35. Perlis R, Sachs G, Lafer B et al. Effect of abrupt change from standard to low serum levels of lithium: a reanalysis of doubleblind lithium maintenance data. Am J Psychiatry 2002; 159:1155-1159. (Pubitemid 34743255)
36. Waters B, Lapierre Y, Gagnon A et al. Determination of the optimal concentration of lithium for the prophylaxis of manic-depressive disorder. Biol Psychiatry 1982; 17:1323-1329. (Pubitemid 13255061)
37. Coppen A, Abou-Saleh M, Milln P, Bailey J, Wood K. Decreasing lithium dosage reduces morbidity and side-effects during prophylaxis. J Affec Dis 1983; 5:353-362. (Pubitemid 14244156)
38. Kleindeinst N, Severus W, Greil W. Are serum lithium levels related to the polarity of recurrence in bipolar disorders? Evidence from a multicenter trial. Int Clin Psychopharm 2007; 22:125-131. (Pubitemid 46562465)
39. Maj M, Starace F, Nolfe G, Kemali D. Minimum plasma lithium levels required for effective prophylaxis in DSM-III bipolar disorder: a prospective study. Pharmacopsychiatry 1986; 19: 420-423. (Pubitemid 17189932)
40. Stein G, Bernadt M. Lithium augmentation therapy in tricyclicresistant depression. A controlled trial using lithium in low and normal doses. Br J Psychiatry 1993; 162:634-640. (Pubitemid 23150996)
41. Nierenberg A, Fava M, Trivedi M et al. A comparison of lithium and T3 augmentation following two failed medication treatments for depression: a STAR * D report. Am J Psychiatry 2006; 163:1519-1530. (Pubitemid 44465751)
42. Satlin A, Liptzin B, Young R. Diagnosis and treatment of late-life bipolar disorder. In: Salzman C, ed. Clinical geriatric psychopharmacology. Philadelphia, PA: Lippincott, Williams and Wilkins, 2005.
43. Juurlink D, Mamdani M, Kopp A, Rochon P, Shulman K, Redelmeier D. Drug-induced lithium toxicity in the elderly: a populationbased study. J Am Geriatr Soc 2004; 52:794-798. (Pubitemid 38596502)
44. Stoudemire A, Hill C, Lewison B, Marquardt M, Dalton S. Lithium intolerance in a medical-psychiatric population. Gen Hosp Psychiatry 1998; 20:85-90. (Pubitemid 28217329)
45. Oakley P, Whyte I, Carter G. Lithium toxicity: an iatrogenic problem in susceptible individuals. Aust N Z J Psychiatry 2001; 35: 833-840. (Pubitemid 34048456)
46. Royal College of Pathologists of Australasia. R CPA Manual. Sydney: Royal College of Pathologists of Australasia, 2009.
47. Roshanaei-Moghaddam B, Katon W. Premature mortality from general medical illnesses among persons with bipolar disorder: a review. Psychiatr Serv 2009; 60:147-156.
48. Phelan M, Stradins L, Morrison S. Physical health of people with severe mental illness can be improved if primary care and mental health professionals pay attention to it. BMJ 2001; 322:443-444. (Pubitemid 32238800)